ZG006

BIOLOGICAL10 trials

Conditions

Neuroendocrine CancerNeuroendocrine CarcinomaNeuroendocrine Prostate CancerSmall Cell Lung CancerSmall-cell Lung CancerSolid Tumor

Phase 1

Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

RecruitingNCT05978284

Suzhou Zelgen Biopharmaceuticals Co.,LtdNeuroendocrine Carcinoma, Small Cell Lung Cancer

Start: 2023-10-27End: 2026-10-31Target: 54Updated: 2026-01-05

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

RecruitingNCT06283719

Suzhou Zelgen Biopharmaceuticals Co.,LtdNeuroendocrine Cancer, Small Cell Lung Cancer

Start: 2024-09-02End: 2026-04-30Target: 265Updated: 2025-11-17

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.

RecruitingNCT06440057

Suzhou Zelgen Biopharmaceuticals Co.,LtdNeuroendocrine Carcinoma

Start: 2024-08-29End: 2026-07-31Target: 78Updated: 2024-12-16

A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

RecruitingNCT06592638

Suzhou Zelgen Biopharmaceuticals Co.,LtdSmall Cell Lung Cancer

Start: 2025-03-31End: 2027-06-30Target: 30Updated: 2025-08-06

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

RecruitingNCT07038096

Suzhou Zelgen Biopharmaceuticals Co.,LtdNeuroendocrine Carcinoma, Small Cell Lung Cancer

Start: 2025-09-23End: 2027-09-30Target: 350Updated: 2026-01-05

Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer

RecruitingNCT07231445

Suzhou Zelgen Biopharmaceuticals Co.,LtdSmall Cell Lung Cancer

Start: 2026-04-21End: 2028-12-01Target: 100Updated: 2026-04-28

Study of ZGGS34 in Participants With Advanced Solid Tumors

RecruitingNCT07258121

Suzhou Zelgen Biopharmaceuticals Co.,LtdSolid Tumor

Start: 2025-12-31End: 2028-12-01Target: 400Updated: 2026-04-28

Phase 2

Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

Not yet recruitingNCT07024277

Suzhou Zelgen Biopharmaceuticals Co.,LtdNeuroendocrine Prostate Cancer

Start: 2025-08-31End: 2027-12-31Target: 60Updated: 2025-06-17

Phase 3

Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer

RecruitingNCT07189455

Suzhou Zelgen Biopharmaceuticals Co.,LtdSmall-cell Lung Cancer

Start: 2025-12-12End: 2028-12-31Target: 420Updated: 2026-01-05

A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma

Not yet recruitingNCT07595913

Suzhou Zelgen Biopharmaceuticals Co.,LtdNeuroendocrine Carcinoma

Start: 2026-07-01End: 2028-12-01Target: 240Updated: 2026-05-19

Related Papers

A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer.

Journal of Clinical Oncology2025-05-283 citations

A phase 1 dose escalation and expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma.

Journal of Clinical Oncology2025-05-281 citations

A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced neuroendocrine carcinoma.

Journal of Clinical Oncology2025-05-28